| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.08. | Northwest Biotherapeutics, Inc.: Northwest Biotherapeutics Announces MOU for Collaboration With the Saudi Pharmaceutical Industries and Medical Appliance Company | 732 | PR Newswire | SPIMACO is One of the Largest Saudi Pharma Companies and a Leader in 21 Markets Across the MENA RegionBETHESDA, Md., Aug. 6, 2026 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) (the... ► Artikel lesen | |
| 31.07. | NORTHWEST BIOTHERAPEUTICS INC - 8-K, Current Report | 9 | SEC Filings | ||
| 18.07. | NORTHWEST BIOTHERAPEUTICS INC - 8-K, Current Report | 4 | SEC Filings | ||
| 13.07. | Original-Research: Northwest Biotherapeutics Inc. (von First Berlin Equity Research GmbH): Buy | 326 | EQS Group (EN) | Original-Research: Northwest Biotherapeutics Inc. - from First Berlin Equity Research GmbH
13.07.2026 / 14:39 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The... ► Artikel lesen | |
| 08.07. | Northwest Biotherapeutics, Inc.: Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses | 757 | PR Newswire | Scientific Presentation at British Neuro-Oncology Annual Meeting Shows Original Analysis of Survival Extension Was Likely UnderestimatedBETHESDA, Md., July 8, 2026 /PRNewswire/ -- Northwest... ► Artikel lesen | |
| 02.07. | Northwest Biotherapeutics, Inc.: Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting | 624 | PR Newswire | BETHESDA, Md., July 2, 2026 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax personalized immune therapies for solid... ► Artikel lesen | |
| NORTHWEST BIOTHERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 02.07. | Northwest Biotherapeutics CTO to present at neuro-oncology meeting | 5 | Investing.com | ||
| 28.05. | Original-Research: Northwest Biotherapeutics Inc. (von First Berlin Equity Research GmbH): BUY | 387 | EQS Group (EN) | Original-Research: Northwest Biotherapeutics Inc. - from First Berlin Equity Research GmbH
28.05.2026 / 13:43 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The... ► Artikel lesen | |
| 30.04. | Northwest Biotherapeutics, Inc.: Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform | 575 | PR Newswire | BETHESDA, Md., April 30, 2026 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax personalized immune therapies... ► Artikel lesen | |
| 21.04. | Northwest Biotherapeutics, Inc.: Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic | 447 | PR Newswire | BETHESDA, Md., April 21, 2026 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax personalized immune therapies... ► Artikel lesen | |
| 15.04. | NORTHWEST BIOTHERAPEUTICS INC - 10-K, Annual Report | 1 | SEC Filings | ||
| 07.04. | Northwest Biotherapeutics schließt Übernahme von Advent BioServices ab | 15 | Investing.com Deutsch | ||
| 07.04. | NORTHWEST BIOTHERAPEUTICS INC - 8-K, Current Report | - | SEC Filings | ||
| 31.03. | NORTHWEST BIOTHERAPEUTICS INC - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | 4 | SEC Filings | ||
| 24.03. | Original-Research: Northwest Biotherapeutics Inc. (von First Berlin Equity Research GmbH): Buy | 446 | EQS Group (EN) | Original-Research: Northwest Biotherapeutics Inc. - from First Berlin Equity Research GmbH
24.03.2026 / 16:01 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The... ► Artikel lesen | |
| 20.11.25 | Northwest Biotherapeutics, Inc.: Northwest Biotherapeutics Announces That Construction Activities Are Under Way For the First Grade C Manufacturing Suite in the Sawston, UK Facility | 741 | PR Newswire | BETHESDA, Md., Nov. 20, 2025 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax personalized immune therapies... ► Artikel lesen | |
| 24.10.25 | Northwest Biotherapeutics, Inc.: Northwest Biotherapeutics Announces That Its Acquisition of Advent BioServices Ltd. Has Closed | 1.152 | PR Newswire | BETHESDA, Md., Oct. 24, 2025 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (OTCQB:NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized immune... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 88,30 | +0,11 % | BioNTech Aktie: Im Rausch der Moderna-Euphorie - Doch wie lange hält die Party an? | © Foto: von fernando zhiminaicela auf Pixabay (Symbolbild)Fast 30 Prozent in einer einzigen Woche. Das ist lange her, dass sowas bei BioNTech vorkam. Zuletzt wohl zu Pandemie-Zeiten ging es mal so zur... ► Artikel lesen | |
| EVOTEC | 3,348 | -1,06 % | BioTech: Übernahmen! Der Kampf um Marktanteile bei Novo Nordisk und Eli Lilly, BioNxt und Evotec auf dem M&A-Radar | Wie die jüngste, spektakuläre 43-Milliarden-USD-Übernahme des Krebsspezialisten Seagen durch Pfizer oder die Mega-Deals rund um die GLP-1-Infrastruktur eindrucksvoll zeigen, befindet sich die Pharmabranche... ► Artikel lesen | |
| BB BIOTECH | 59,40 | -0,17 % | Edison Investment Research Limited: Edison issues report on BB Biotech (BION) | Edison Investment Research Limited
Edison issues report on BB Biotech (BION) 28-Jul-2026 / 14:20 GMT/BST
The issuer is solely responsible for the content of this announcement.
... ► Artikel lesen | |
| MEDIGENE | 0,006 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 30.06.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 30.06.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 30.06.2026ISIN NameBE0003593044 COFINIMMOCA8765111064 TASEKO... ► Artikel lesen | |
| QIAGEN | 37,590 | -0,42 % | QIAGEN ernennt Jonathan M. Pratt zum Vorstandschef | Bad Marienberg (www.anleihencheck.de) - QIAGEN N.V. ((ISIN NL0015001WM6/ WKN A41HBE; NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute die Ernennung von Jonathan M. Pratt zum Vorstandsvorsitzenden... ► Artikel lesen | |
| MODERNA | 119,06 | -0,03 % | Moderna explodiert 177 gelingt jetzt das große Comeback? | ||
| VALNEVA | 2,798 | +0,76 % | Katalysator voraus: Valneva (ISIN: FR0004056851) setzt auf Q3-Shigella-Daten | ||
| AMGEN | 371,90 | -0,35 % | Amgen: Tezspire Demonstrates Positive Phase 3 Results In Eosinophilic Esophagitis Across Both Co-primary And All Key Secondary Endpoints | Statistically Significant and Clinically Meaningful Disease and Symptom Improvements Compared to Placebo Maintained Through Week 52
Efficacy in a Third Epithelial-Driven... ► Artikel lesen | |
| EPIGENOMICS | 0,900 | -1,10 % | PTA-Adhoc: Epigenomics AG: Vorläufiges Halbjahresergebnis zum 30. Juni 2026 | DJ PTA-Adhoc: Epigenomics AG: Vorläufiges Halbjahresergebnis zum 30. Juni 2026
Veröffentlichung von Insiderinformationen gemäß Artikel 17 MAR Schlagwort(e): Geschäftszahlen / Halbjahr
Epigenomics... ► Artikel lesen | |
| NOVAVAX | 7,950 | -0,62 % | Novavax announces regulatory approvals for updated COVID shot | ||
| STRYKER | 285,30 | -0,07 % | Do Options Traders Know Something About Stryker Stock We Don't? | ||
| BIOGEN | 187,62 | -0,51 % | Veeva Systems: Veeva Vault CRM Selected by Biogen | Unified commercial platform to help speed the delivery of medicines to patientsPLEASANTON, Calif., Aug. 25, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Biogen has... ► Artikel lesen | |
| BIOFRONTERA | 2,500 | +2,46 % | PTA-Adhoc: Biofrontera AG: Biofrontera AG beschließt Vorbereitung des Wechsels vom regulierten Markt (Prime Standard) in das Börsensegment Scale | DJ PTA-Adhoc: Biofrontera AG: Biofrontera AG beschließt Vorbereitung des Wechsels vom regulierten Markt (Prime Standard) in das Börsensegment Scale
Veröffentlichung von Insiderinformationen gemäß... ► Artikel lesen | |
| HEIDELBERG PHARMA | 2,610 | +1,16 % | EQS-News: Heidelberg Pharma AG und Huadong Medicine erhalten NMPA-Genehmigung für klinische Studie mit HDP-101 als Kombinationstherapie in China | EQS-News: Heidelberg Pharma AG
/ Schlagwort(e): Studie
Heidelberg Pharma AG und Huadong Medicine erhalten NMPA-Genehmigung für klinische Studie mit HDP-101 als Kombinationstherapie... ► Artikel lesen | |
| ILLUMINA | 186,64 | +0,27 % | $100 Invested In Illumina 20 Years Ago Would Be Worth This Much Today |